Hypoplastic left heart syndrome [HLHS] : treatment options in present era by unknown
REVIEW ARTICLE
Hypoplastic left heart syndrome [HLHS]: treatment options
in present era
Vivek Rai1 & Marcin Gładki1 & Mirosława Dudyńska1 & Janusz Skalski1
Received: 13 June 2018 /Revised: 2 September 2018 /Accepted: 7 September 2018 /Published online: 31 October 2018
# The Author(s) 2018
Abstract
Hypoplastic left heart syndrome (HLHS) is the most severe form of congenital heart defect (CHD). The first successful
intervention for it was undertaken by Norwood in 1983. Since then, there have been much development in the pre, intra,
and postoperative treatment option in staged palliative surgical procedures. Early diagnostic management, prenatal
interventions, innovative diagnostic methods, constantly modified surgical techniques, and hybridization contribute to
a significant progress in treatment options. This will allow for defining an optimal strategy of improving survival and
quality of life in HLHS patients. The development of intervention cardiology makes possible the stepwise treatment of
the defect with one operation only. The first and third stage may be done by hybrid or interventional methods, then only
the second stage of treatment needs to be done surgically. The world experience and all the available literature says that
the 1st-stage procedure could be done now safely either directly or with a bridge to Norwood followed by the stage 2
with a Glen or Hemi-Fontan and followed by a Fontan down the lane surgically.
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Introduction
HLHS is the most severe form of CHD, representing car-
diac malformations that are characterized by severe under-
development of the structures in the left heart-aorta com-
plex, including the left ventricular cavity and mass. The
term potentially denotes any malformation that involves
underdevelopment of the left-sided cardiac structures
from aortic stenosis and coarctation of the aorta to the
other extremes involving aortic atresia, mitral atresia,
and hypoplasia of the ascending aorta. Statistically, about
1.25% children with congenital heart defects are patients
with single ventricle heart [1]. The majority of untreated
newborns die within the first 7–10 days of life.
Prenatal diagnosis
Development in the field of ultrasonography has allowed for
recognizing early HLHS in the first trimester of fetal life, which
helps in further planning and making decision whether to pro-
ceedwith pregnancy. Anatomical defects in HLHSwhichwors-
en the prognosis are restrictive atrial connection, tricuspid re-
gurgitation, and ventricular dysfunction [2]. The percentage of
neurological complications is lower, due to early recognizing
HLHS [3]. In some countries, where pregnancy termination
rates are relatively high, a higher number of prenatal diagnoses
caused a decrease in the birth rate of children with HLHS [4].
Fetal interventions in HLHS have been developed in order to
improve hemodynamics and prevent the development of de-
fects. Currently, two types of treatment are used in case of this
defect: balloon septostomy in case of restrictions of the atrial
septum and balloon valve surgery in cases of critical aortic
stenosis. In both cases, the treatment is performed under guid-
ance of ultrasound (fetal echocardiography). The procedure
must be done in very experienced centers because in 20% of
such interventions, loss of the fetus is involved [5].
During prenatal intervention, it is also possible to per-
form a thorough genetic diagnostic management. Indeed,
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the cause of the defect is multifactorial and not stable. The
established risk of recurrence of the defect in future preg-
nancies is 2–4%, and in families with two children with this
disadvantage, it reaches 25% [6].
Heart transplant
Heart transplant in a newborn with HLHS is also an available
treatment option. The procedure always entails the risk of
organ rejection and complications associated with immuno-
suppression [infection, tumor]. In the present era, this method
is still limited due to scarcity of donors [7]. In newborns,
hearts to be transplanted may be harvested from non-
compliant donors (ABO-incompatible), thanks to the imma-
ture immune system in neonates [8]. The quality of life after
heart transplant is better as compared to patients with staged
palliative surgery [9].
Heart transplantation is also a possible treatment modality
in cases of extreme heart failure after the Fontan procedure,
especially when the background is dysfunction of the ventri-
cle. This is a high-risk procedure in patients being treated by
heart transplant, but if successful, it provides a good quality of
life in this group of patients [10]. Ventricular assist device
(VAD) support can be used as a bridge to transplant in
HLHS patients.
Palliative treatment
Palliative treatment is the most commonly used method of
treatment. This method includes three stages of treatment.
The first stage called the Norwood operation takes place in
the neonatal period, the second stage is the hemi-Fontan
(HF) or Glenn procedures performed at around 4–6 months
of life, and the final stage is the Fontan operation which
takes place around 18–24 months of age [11]. Since 1983,
there has been much advancement in pre, intra, and postop-
erative care in HLHS. With progress in the field of cardiac
surgery and introduction of various modifications in the
stage treatment, there is a significant improvement in sur-
vival rates [12]. Despite improving results and more surgi-
cal procedures, children with HLHS require constant multi-
specialty adapting care.
Norwood procedure
The aim of this procedure is to use the right ventricle as the
main pumping ventricle for systemic circulation. To achieve
this goal, the following steps in the operation are taken:
i. Connection between the right ventricle and aorta is created
with the aid of a pulmonary homograft (neoaorta).
ii. Developing a new source of pulmonary blood flow via the
systemic-to-pulmonary artery shunt: modifed Blalock-
Taussig (MBT) shunt or right ventricle-to-pulmonary ar-
tery (RV-PA) shunt. The shunt is a long-term replacement
for prostaglandin E1 (PGE1), which was used preopera-
tively for PGE1-dependent ductus arteriosus (DA)
patency.
iii. An atrial septectomy to secure good atrial communica-
tion, which is required to permit pulmonary venous re-
turn to reach the right ventricle. If restrictive atrial septum
is present, then the Rashkind procedure along with stent
implantation should be performed.
At conclusion, the right ventricle provides blood to both
circulation systems in parallel, as opposed to two-ventricle
physiology where blood flow is in-series. Ideally, blow flow
should have a similar ratio in both circulation systems, i.e.,
Qp:Qs at 1:1.
In the Norwood anatomy and physiology, there is mixing
of blood due to atrium septum. As a result, the typical arte-
rial oxygen saturation values in these children are in the
range of 75–85%. Such lower arterial oxygen saturation
values (as compared with normal individuals) are surpris-
ingly well-tolerated.
The source of pulmonary blood flow (PBF) by using a
Gore-Tex(polytetrafluorethylene) tube implanted between
the right innominate or subclavian artery and the right pul-
monary artery constitute modifications of the Blalock-
Taussig (B-T) shunt. The modification is based on a descrip-
tion by Alfred Blalock and Helen Taussig in 1945 [13, 14].
This modified shunt is known as the MBT shunt. The shunt
is typically 3.5 mm in diameter, so that there is optimal flow
and excessive flow to the lung is avoided. The MBT shunt
allows for blood flow also in diastolic phase into the pulmo-
nary vasculature and away from the coronary perfusion,
which gives rise to development of the coronary steal phe-
nomenon. As a result, there is volume load on the single
ventricle and a decreased myocardial function, arrhythmias,
and sudden cardiac death [15]. Acute shunt thrombosis—
partial or total—is also a possible complication which may
generate life-threatening hypoxemia [16]. To regulate these
detrimental physiological features, as an alternative to the
MBT shunt, the RV-PA shunt was developed.
Anastomosis between the right ventricle and pulmo-
nary artery trunk is known as the RV-PA shunt, located
on the right or left side of reconstruction of the neoaorta.
Norwood and colleagues initially described the RV-PA
conduit, but the reported method was long ignored [17].
Earlier, there had been many attempts at creating a RV-PA
shunt in single ventricle patients [18–20].The RV-PA con-
duit has seen a dramatic revival in popularity since its re-
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introduction by Sano [21]. RV-PAs have an advantage as
compared to MBT shunt because it prevents coronary
steal during diastole that could potentially contribute to
the improvement of treatment outcomes in the inter-
stage period [22, 23].The RV-PA shunt requires a right
ventriculotomy and the non-valved nature of the conduit
may lead to regurgitant flow, which could potentially lead
to ventricular dysfunction in an already stressed
univentricular heart. These disadvantages may cause ven-
tricular arrhythmias and impair the systemic right ventri-
cle function [24]. The choice between these two sources
of PBF is currently surgeon or institution-dependent.
Many single institutions published articles, comparing
the traditional B-T shunt vs. the RV-to-PA conduit [25,
26]. Because of the conflicting results and limitations
due to single-center retrospective studies, trials were
needed for solving this question. The Pediatric Heart
Network published a multicenter randomized trial in in-
fants with HLHS undergoing the Norwood procedure,
known as the Single Ventricle Reconstruction (SVR) trial
[27]. In this trial, 555 patients were randomized to either a
MBT shunt or an RV-PA conduit groups. There were 72
deaths or cardiac transplants in the RV-PA shunt group,
and 100 deaths or cardiac transplants in the MBT shunt
group. On the basis of the data, the RV-PA shunt as com-
pared to the MBT was found to be associated with an
improved transplantation-free survival at 12 months.
Two studies from SVR trials described in-hospital and
inter-stage mortality associated with the Norwood proce-
dure as being 16% irrespectively of shunt type. The inter-
stage mortality between stage I and II was 6% for the RV-
PA conduit, and 18% for the MBT shunt. The 3-year fol-
low-up for transplant-free survival in the SVR trial did not
differ by shunt types [28].
The most recent study identified an association between
digoxin and reduced mortality following hospital discharge
after the Norwood procedure using SVR data [29].
A study that investigated preoperative risk factors, using
the database from the Society of Thoracic Surgeons, found
that weight below 2.5 kg, preoperative shock, non-cardiac
or genetic abnormalities, preoperative mechanical ventila-
tory or circulatory support, a small ascending aorta, an
intact/restrictive interatrial septum, and the variant of
HLHS with aortic atresia and mitral stenosis led to postop-
erative complications [30].
In a recent study from the Congenital Heart Surgeon’s
Society, the propensity scores were used to compare 169
RV-PA conduit with 169 MBT shunt patients. There was
better 6-year survival with the RV-PA (70%) conduit ver-
sus the MBT shunt (55%). The MBT shunt showed a
lower transplant-free survival and right ventricular dys-
function with moderate to severe atrioventricular valvular
regurgitation [31].
Hybrid procedures
The hybrid procedure represents a less intensive approach that
combines interventional cardiac catheterization with off-
cardiopulmonary bypass surgery, first reported in 1993 [32].
Cardiopulmonary bypass use in neonates with cardiac and
non-cardiac comorbidities might lead to neurological compli-
cations; thus, an alternative to CBP became the origin of hy-
brid approach in HLHS patients.
The hybrid procedure achieves the same goals as the stan-
dard Norwood procedure in a less intensive manner, which
can be described as follows:
i. systemic perfusion is maintained with a ductal arteriosus
stent.
ii. unrestricted pulmonary venous return is accomplished
with either surgical atrial septectomy or a balloon atrial
septostomy.
iii. controlled (diminished) PBF is accomplished with pul-
monary artery bands on the right and the left pulmonary
artery.
After the inter-stage period, the comprehensive stage I + II
includes the removal of the PA bands, removal of the ductal
stent, and repair of the aortic arch and pulmonary arteries.
Removing the ductal stent is probably the most challenging
element. It takes a technique similar to an endarterectomy to
safely extract the stent without injuring the descending thorac-
ic aorta. Initially, the hybrid approach was used for high-risk
infants. With formal or relative contraindications to the
Norwood stage I operation, single-center studies showed the
feasibility of the approach, and others started using it on stan-
dard risk patients as an alternative to the Norwood stage I
procedure [33].
The pioneering work by Galantowicz and colleagues [34]
was very illustrative in demonstrating what can be accom-
plished with the hybrid approach for HLHS. Sixty-two pa-
tients underwent the hybrid stage I procedure. The results
were impressive, with the hospital survival after the hybrid
stage I reaching 97.5%. In the inter-stage I–II interval, two
patients died. The hospital survival during the comprehensive
stage I + II was 92%. The most important point derived from
this early experience is that in certain patients with unfavor-
able anatomy, namely those with aortic atresia and no
antegrade flow to the coronary arteries, jailing by the ductal
stent may create stenosis of the retrograde orifice to the trans-
verse arch. These patients should be identified before inter-
vention, because a ductal stent can acutely lead to head vessel
and/or coronary artery flow compromise, potentially leading
to death from myocardial infarction and circulatory collapse.
The options are to offer these patients the standard Norwood
procedure or to stent the retrograde orifice at the time of the
patent ductus arteriosus (PDA) stent [35].
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The group in Giessen recently described 182 babies that
underwent this hybrid strategy [36]. At 10 years, the probabil-
ity of survival is 77.8%. Aortic arch re-interventions were only
needed in 16.7% of patients. A benefit of this approach was
that several of the patients were able to be transitioned to the
biventricular repair after the hybrid approach instead of the
single ventricle palliation.
Hybrid-bridge-to-Norwood
The need for more catheterizations and the concerns about
removing the stent during the comprehensive stage I + II led
to the revival of another sequence of operations once de-
scribed by Dr. Norwood, called the hybrid-bridge-to-
Norwood or the Bsalvage-bridge-to-Norwood^ [37]. In high-
risk HLHS neonates with concomitant cardiac and non-
cardiac comorbidities, in whom the initial Norwood stage I
operation is deemed prohibitive, the sequence starts with bi-
lateral pulmonary artery bands in the early period after birth.
The ductus is kept open with prostaglandins, instead of a me-
chanical stent. The Norwood stage I is then performed after
the baby is stabilized, typically at about 2 weeks of age. The
Bhybrid-bridge-to-Norwood^ or Bsalvage-to-Norwood^ ap-
proach gives the baby time to recover and allows time for
the surgeon to undertake the Norwood stage I at a more ad-
vantageous moment. Although the in-hospital mortality with
the Bsalvage-to-Norwood^ approach is high as compared to
other approaches in neonates with HLHS, it is the only alter-
native to certain death in an otherwise very high-risk and
unstable situation.
Inter-stage period
The period of time between hospital discharge after the
Norwood procedure and the stage II surgery is commonly
referred to as the inter-stage period. During the inter-stage
period, accurate monitoring of the patient and cardiologic ex-
amination is important. After implementing parental educa-
tion and home monitoring program (measuring systemic
blood oxygenation with pulse oximeter, and changes in
weight), there is a reduced complication rate and better sur-
vival [38]. Mortality between stages is 4–15%. The main
causes of death are as follows: ventricular dysfunction, steno-
sis of the carotid artery or aortic arch, restriction of the atrial
septum, coronary circulation disorders, and stenosis or
systemic-pulmonary systemic obstruction [39].
The most common re-interventions after the first stage of
treatment are also associated with problems. Stenosis of the
aorta appears with an incidence of about 5–10% and in the
majority of cases, it is effectively resolved by the method of
transcutaneous balloon plastic surgery. Invasive cardiology
techniques are also used for implantation of stents into the
formation of stenosis of the anastomosis. Tricuspid valve sur-
gery and interventions within pulmonary stenosis are per-
formed during the second stage of treatment [35].
Second stage of treatment
Currently, two basic surgical techniques are used: the hemi-
Fontan operation or bidirectional Glenn anastomosis. The en-
ergy loss in the lateral intra-atrial tunnel (the third stage of
treatment) produced after the previous hemi-Fontan operation
is significantly lower compared to the energy dissipation in
the tunnel produced after Glenn’s two-way operation. More
physiological distribution of blood to both lungs after the
hemi-Fontan surgery has been also noted [40]. The second
stage of treatment after previous treatment hybridization is a
more complicated and longer operation. It is a combination of
the Norwood operation and hemi-Fontan operation and in
some centers also serves as preparation for performing the
third stage of invasive cardiological defect treatment [34].
The Norwood procedure is undertaken during the time
when the pulmonary vascular resistance is too elevated to
allow a cavopulmonary anastomosis. The second stage is usu-
ally undertaken between 4 and 6 months of age. The goal of
the second stage is to unload the right ventricle. This is ac-
complished with either the bidirectional Glenn or the hemi-
Fontan. The advantage of the bidirectional Glenn is that it can
potentially be performed off-pump and is an easier connec-
tion. The hemi-Fontan makes the final stage more straightfor-
ward. This second stage originally was proposed as an interim
palliation only for high-risk babies before undergoing the
Fontan operation [41], instead of proceeding directly from a
shunted physiology to total cavopulmonary connection
(TCPC) in one step, which is a huge physiological change
associated with a high risk of failure. After the staged pallia-
tion with the interim Glenn operation, breaking the adaptation
to new cardiopulmonary flows into two lower-risk steps with
better results, the Glenn operation became a standard staging
procedure even in babies with a low-risk profile, leading to the
current three-stage approach. The goal is to unload the ventri-
cle as early as possible, minimize the potential steal from
coronary blood flow, and limit the amount of time the pulmo-
nary vasculature is exposed to systemic pressures before the
baby can tolerate the Fontan [42].
Traditionally, the bidirectional Glenn anastomosis was sit-
uated between the superior vena cava and the pulmonary ar-
teries. The inferior vena cava to pulmonary artery anastomosis
was abandoned in the animal lab by Dr. Glenn after repeated
failures in his animal models. In patients with unfavorable
upper body systemic venous anatomy, the superior vena cava
(SVC)-pulmonary artery (PA) connection is suboptimal or not
feasible, and an alternative is needed to unload the heart. As it
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was demonstrated by studies, this subset of patients may ben-
efit from the primary inferior vena cava (IVC)-pulmonary
artery (PA) connection, the BSouthern Glenn,^ which we have
performed successfully in two patients [43].
Third stage of treatment—Fontan procedure
The Fontan operation typically connects the IVC to the right
pulmonary artery (RPA) leading to a total cavopulmonary
connection so that all PBF is achieved passively. In-series
circulation is restored and saturation achieves near-normal
levels. This typically happens between 24 and 48 months of
age. There are numerous single institution series investigating
the short- and long-term outcomes and predictors of mortality
and morbidity after the Fontan completion [44, 45]. The con-
sistent predictors of poor outcome across multiple studies are
longer cross-clamp times, longer duration of hospital stay,
heterotaxy, and atrioventricular valve anomaly.
The concept of the Fontan operation was first applied to a
patient with tricuspid atresia by Francis Fontan in 1968 [46],
but it has since become the final surgical stage for patients
with HLHS. The goal of this ingenious operation is to direct
the desaturated systemic venous return from the inferior
vena cava into the pulmonary circulation, which may be
done either via a lateral tunnel or extracardiac conduit that
connects the inferior vena cava to the pulmonary artery. In
some patients, small fenestration may be created in the
Fontan conduit, a modification aimed at providing children
with this unique anatomy and physiology with another
means to fill their single ventricle, albeit with desaturated
blood [47]. This practice may be especially helpful in pa-
tients with relatively high pulmonary vascular pressure
values, although studies attempting to discern the merits
of these theoretical benefits have been conflicting [47, 48].
Total venous-pulmonary connection may also be done by
intervention cardiology via a polytetrafluorethylene-covered
stent (covered stent) [49]. Balloon expansion under the control
of angiography and echocardiography allows for an accurate
placement of the stent in the correct position. This procedure
requires prior preparation in II stage of treatment. The advan-
tage is it may be done without ECMO support.
The strategy of using hybrid procedures will apply to few
subsets and will not be a norm. Moreover, majority of centers
are not very comfortable with Norwood Glen at stage 2 with
retrieval of the stent to repair the arch which seems possible
but likely to have sequels as arch obstruction and pulmonary
artery plasty following the bilateral PA bands, pulmonary ar-
tery anatomy being the most important factor for influencing
the outcome of the single ventricle repair. The sequential sur-
gical procedures with good outcomes practiced in a good
number of centers in the world are presented in (Table 1).
An unsolvable problem remains in any path taken
(Surgical/interventional/Hybrid), for the staged palliation
which is a ventricular function which is the real Achilles heel
of these repairs. The possibility of use of a ventricular pump in
future might be a reality to sort out this issue.
Conclusions
There are widespread modifications of the Norwood opera-
tions which significantly improve HLHS results. Early diag-
nostic management, prenatal interventions, innovative diag-
nostic methods, constantly modified surgical techniques, and
hybridization contribute to a significant progress in treatment
Table 1 The sequential surgical procedures for single-ventricle palliation (SVP)
Study name The sequential surgical procedures
Emani et al. 2012 [50] Stage 1 - > BDG - > Fotan - > cardiac transplantation
OR
Stage 1 - > BDG - > biventricular conversion - > cardiac transplantation.
Malec et al. 2000 [51] Stage 1 with mBTS - > stage II (hemi-Fontan) and stage III (modified Fontan).
McGuirk et al. 2006 [52] Norwood procedure - > bidirectional Glenn procedure (stage II) - > a modified Fontan procedure (stage III)
Andrews et al. [53] stage I (the Norwood operation) - > stage II (the hemi-Fontan operation - >
stage III (the Fontan operation - > cardiac transplantation
Rogers et al. 2012 [54] stage I (mBTS) - > stage II (BDG) - > stage III extracardiac conduit (ECC) Fontan - > cardiac transplantation
or
stage I (RV-PA)- > stage II (the hemi-Fontan operation - > stage III (the Fontan operation - > cardiac transplantation
Malec et al. 2017 [55] stage I (mBTS) - > stage II (BDG) - > stage III extracardiac conduit (ECC) Fontan - > cardiac transplantation
or
stage I (RV-PA)- > stage II (the hemi-Fontan operation - > stage III (the Fontan operation - > cardiac transplantation
Rai et al. 2018.[56] stage I (RV-PA)- > stage II (the hemi-Fontan operation - > stage III (the Fontan operation - > cardiac transplantation
BDG bidirectional Glenn procedure, mBTS modifed right Blalock-Taussig shunt, ECC extracardiac conduit, IALT intra-atrial lateral tunnels, HF hemi-
Fontan, RV-PA the right ventricle-to-pulmonary artery shunt
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options. This will allow for defining an optimal strategy of
improving survival and quality of life in HLHS patients. The
world experience and a lot of the available literature say that.
The 1st-stage procedure could be done now safely either di-
rectly or with a bridge to Norwood followed by the stage 2
with a Glen or Hemi-Fontan and followed by a Fontan down
the lane surgically.
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